Cargando…

A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass

OBJECTIVE: To determine changes in incretins, systemic inflammation, intestinal permeability and microbiome modifications 12 months after metabolic RYGB (mRYGB) in patients with type 2 diabetes (T2D) and their relationship with metabolic improvement. MATERIALS AND METHODS: Prospective single-center...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hernández-Montoliu, Laura, Rodríguez-Peña, M-Mar, Puig, Rocío, Astiarraga, Brenno, Guerrero-Pérez, Fernando, Virgili, Nuria, López-Urdiales, Rafael, Osorio, Javier, Monseny, Rosa, Lazzara, Claudio, Sobrino, Lucía, Pérez-Maraver, Manuel, Pérez-Prieto, María, Pellitero, Silvia, Fernández-Veledo, Sonia, Vendrell, Joan, Vilarrasa, Nuria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616869/ https://www.ncbi.nlm.nih.gov/pubmed/37916149 http://dx.doi.org/10.3389/fendo.2023.1181744

Ejemplares similares

Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes
por: Ejarque, Miriam, et al.
Publicado: (2019)

Impaired Succinate Response to a Mixed Meal in Obesity and Type 2 Diabetes Is Normalized After Metabolic Surgery
por: Astiarraga, Brenno, et al.
Publicado: (2020)

Long-Term Effects in Bone Mineral Density after Different Bariatric Procedures in Patients with Type 2 Diabetes: Outcomes of a Randomized Clinical Trial
por: Guerrero-Pérez, Fernando, et al.
Publicado: (2020)

Changes in glucagon‐like peptide 1 and 2 levels in people with obesity after a diet‐induced weight‐loss intervention are related to a specific microbiota signature: A prospective cohort study
por: Rodríguez‐Peña, M‐Mar, et al.
Publicado: (2021)

Erratum. Preoperative Circulating Succinate Levels as a Biomarker for Diabetes Remission After Bariatric Surgery. Diabetes Care 2019;42:1956–1965
por: Ceperuelo-Mallafré, Victoria, et al.
Publicado: (2019)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

Is Trabecular Bone Score Valuable in Bone Microstructure Assessment after Gastric Bypass in Women with Morbid Obesity?
por: Marengo, Agustina Pia, et al.
Publicado: (2017)

Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study
por: Pérez-Durillo, Francisco Tomás, et al.
Publicado: (2018)

Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass
por: Pérez-Arana, Gonzalo-Martín, et al.
Publicado: (2022)

CORRELATION BETWEEN PRE AND POSTOPERATIVE LEVELS OF GLP-1/GLP-2 AND WEIGHT LOSS AFTER ROUX-EN-Y GASTRIC BYPASS: A PROSPECTIVE STUDY
por: CAZZO, Everton, et al.
Publicado: (2016)

Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass
por: Jonsson, Isabella, et al.
Publicado: (2021)

A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice
por: Hornigold, David C., et al.
Publicado: (2018)

Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1
por: Zietek, Tamara, et al.
Publicado: (2016)

Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
por: Rowlands, Jordan, et al.
Publicado: (2018)

The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
por: Daniilopoulou, Ioanna, et al.
Publicado: (2022)

Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
por: Miñambres, Inka, et al.
Publicado: (2017)

The Effect of Standard Versus Longer Intestinal Bypass on GLP-1 Regulation and Glucose Metabolism in Patients With Type 2 Diabetes Undergoing Roux-en-Y Gastric Bypass: The Long-Limb Study
por: Miras, Alexander Dimitri, et al.
Publicado: (2021)

GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice
por: Quarta, Carmelo, et al.
Publicado: (2022)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
por: Heidarzadeh, Sara, et al.
Publicado: (2013)

GLP-1 based therapeutics: simultaneously combating T2DM and obesity
por: Heppner, Kristy M., et al.
Publicado: (2015)

Preventing Oxidative Stress in the Liver: An Opportunity for GLP-1 and/or PASK
por: Hurtado-Carneiro, Verónica, et al.
Publicado: (2021)

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass
por: Tharakan, George, et al.
Publicado: (2017)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Discovery of a bacterial peptide as a modulator of GLP-1 and metabolic disease
por: Tomaro-Duchesneau, Catherine, et al.
Publicado: (2020)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

Effect of GLP-1/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis
por: Yang, Li, et al.
Publicado: (2021)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Glucolipotoxicity and GLP-1 secretion
por: Hong, Jung-Hee, et al.
Publicado: (2021)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling
por: Kalra, Sanjay, et al.
Publicado: (2012)

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis
por: Jin, Yue, et al.
Publicado: (2015)

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
por: Meurot, C., et al.
Publicado: (2022)

GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
por: Abdalqadir, Nyan, et al.
Publicado: (2022)

Gut microbiota-derived succinate: Friend or foe in human metabolic diseases?
por: Fernández-Veledo, Sonia, et al.
Publicado: (2019)

GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production: Evidence for Predominance of GLP-2–Stimulated Postprandial Lipemia in Normal and Insulin-Resistant States
por: Hein, Gustavo J., et al.
Publicado: (2013)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3hq2cpvehmm30udv2tsg8qerfc